|
Orthologous residues
|
|
NFkB‑p65 (human): S468‑p, NFkB‑p65 (mouse): S467‑p, NFkB‑p65 (rat): S468‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
electrophoretic mobility shift, mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
HeLa (cervical)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
GSK3B (human)
|
phospho-antibody, modification site within consensus motif, pharmacological inhibitor of upstream enzyme, electrophoretic mobility shift
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
calyculin A
|
|
|
|
increase
|
|
|
lithium
|
calyculin A
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
inhibition
|
|
Effect of modification (process):
transcription, altered
|
